| Expression of secretory phospholipase A2 group IIa in breast cancer and correlation to prognosis in a cohort of advanced breast cancer patients SS Jespersen, ES Stovgaard, D Nielsen, TD Christensen, ASK Buhl, ... Applied Immunohistochemistry & Molecular Morphology 29 (1), e5-e9, 2021 | 9 | 2021 |
| Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective … ASK Buhl, TD Christensen, IJ Christensen, KM Nelausen, E Balslev, ... Breast Cancer Research and Treatment 172, 391-400, 2018 | 6 | 2018 |
| Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay TD Christensen, ASK Buhl, IJ Christensen, IK Buhl, E Balslev, AS Knoop, ... Breast Cancer 27, 266-276, 2020 | 3 | 2020 |
| Doxorubicin response prediction in neoadjuvant breast cancer therapy. ASK Buhl, IJ Christensen, S Knudsen, PB Jensen Journal of Clinical Oncology 37 (15_suppl), e12119-e12119, 2019 | 2 | 2019 |
| Fulvestrant response prediction from transcriptome data obtained from primary breast cancer biopsies. TD Christensen, ASK Buhl, IJ Christensen, KM Nelausen, E Balslev, ... Journal of Clinical Oncology 34 (15_suppl), e12056-e12056, 2016 | 2 | 2016 |
| Prediction of exemestane benefit in patients with advanced breast cancer based on diagnostic biopsy mRNA analysis. TD Christensen, ASK Buhl, IJ Christensen, KM Nelausen, E Balslev, ... Journal of Clinical Oncology 35 (15_suppl), e12532-e12532, 2017 | 1 | 2017 |
| Therapeutic drug monitoring of imatinib–how far are we in the leukemia setting? AS Buhl Rasmussen, CL Andersen, A Weimann, T Yang, C Tron, ... Expert Review of Clinical Pharmacology 17 (3), 225-234, 2024 | | 2024 |
| Evaluation of drug-specific multigene markers to predict aromatase inhibitor efficacy in advanced breast cancer: a cohort study from Danish Breast Cancer Cooperative Group IK Buhl, TD Christensen, ASK Buhl, IJ Christensen, E Balslev, AS Knop, ... | | 2019 |
| A drug response predictor to guide treatment for breast cancer IK Buhl, PB Jensen, AS Kappel Buhl, S Knudsen Pharmacogenomics 20 (5), 307-309, 2019 | | 2019 |
| Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group … ASK Buhl, TD Christensen, IJ Christensen, KM Nelausen, E Balslev, ... Journal of Clinical Oncology 35, 2017 | | 2017 |
